Positive News SentimentPositive NewsNASDAQ:JANX Janux Therapeutics (JANX) Stock Price, News & Analysis → These AI trades triggered this morning (545% return) (From Prosper Trading Academy) (Ad) Free JANX Stock Alerts $47.10 -1.11 (-2.30%) (As of 04/25/2024 ET) Add Compare Share Share Today's Range$45.68▼$48.3050-Day Range$9.43▼$52.6552-Week Range$5.65▼$58.69Volume555,331 shsAverage Volume816,338 shsMarket Capitalization$2.43 billionP/E RatioN/ADividend YieldN/APrice Target$61.33 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Janux Therapeutics alerts: Email Address Janux Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside30.2% Upside$61.33 Price TargetShort InterestHealthy9.99% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($1.41) to ($1.64) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.72 out of 5 starsMedical Sector239th out of 908 stocksPharmaceutical Preparations Industry97th out of 423 stocks 4.5 Analyst's Opinion Consensus RatingJanux Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageJanux Therapeutics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 4.0 Short Interest Percentage of Shares Shorted9.99% of the float of Janux Therapeutics has been sold short.Short Interest Ratio / Days to CoverJanux Therapeutics has a short interest ratio ("days to cover") of 3.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Janux Therapeutics has recently decreased by 8.27%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldJanux Therapeutics does not currently pay a dividend.Dividend GrowthJanux Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for JANX. Previous Next 2.6 News and Social Media Coverage News SentimentJanux Therapeutics has a news sentiment score of 1.73. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.38 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Janux Therapeutics this week, compared to 2 articles on an average week.Search InterestOnly 30 people have searched for JANX on MarketBeat in the last 30 days. This is a decrease of -36% compared to the previous 30 days.MarketBeat FollowsOnly 9 people have added Janux Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -10% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Janux Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders35.40% of the stock of Janux Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions75.39% of the stock of Janux Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Janux Therapeutics are expected to decrease in the coming year, from ($1.41) to ($1.64) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Janux Therapeutics is -35.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Janux Therapeutics is -35.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioJanux Therapeutics has a P/B Ratio of 6.31. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad WealthPress$25,000 into $109,616 in two months? Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…Go here to watch the most recent trading workshop video at no charge. About Janux Therapeutics Stock (NASDAQ:JANX)Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma. Its development pipeline also consists of discovery stage products. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.Read More JANX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart JANX Stock News HeadlinesApril 17, 2024 | investorplace.comTake the Money and Run: 3 Overbought Stocks to Sell ASAPApril 17, 2024 | nasdaq.comValidea Detailed Fundamental Analysis - JANXApril 26, 2024 | Prosper Trading Academy (Ad)These AI trades triggered this morning (545% return)If you think a market crash is possible in 2024, I don't know why you're not using this yet.April 17, 2024 | americanbankingnews.comJanux Therapeutics (NASDAQ:JANX) Now Covered by Analysts at JonestradingApril 16, 2024 | msn.comJonesTrading Initiates Coverage of Janux Therapeutics (JANX) with Buy RecommendationApril 16, 2024 | msn.comJanux a new buy at Jones on lead assets for solid tumorsApril 16, 2024 | investorplace.comThese 3 Biotech Stocks Are Up 269% in 2024. Is There More to Come?April 16, 2024 | benzinga.comA Glimpse Into The Expert Outlook On Janux Therapeutics Through 6 AnalystsApril 26, 2024 | Insiders Exposed (Ad)The Hard Truth About Investing For RetirementHere’s the cold, hard truth about investing: The more capital you have, the more risk averse you can afford to be. But when you’re staring down the barrel of retirement and you’ve only got 5, 10, 50 or $100,000 saved, you’ve got to be more aggressive. In an exclusive online training, the Market expert Steven Place is revealing a powerful “roadmap” that’s leading everyday investors to easy, triple-digit wins, even if they don’t have a lot of experience in trading.April 12, 2024 | fool.comWhy Janux Therapeutics Stock Is Crushing It This WeekApril 11, 2024 | theglobeandmail.comStocks See Continued Pressure as Bond Yields ClimbApril 11, 2024 | benzinga.comWhy Is Cancer-Focused Janux Therapeutics Stock Trading Higher On Thursday?April 11, 2024 | finance.yahoo.comBiotech Stocks Heat Up As Arvinas Scores Novartis Licensing Pact, Janux Reportedly Explores OptionsApril 11, 2024 | investors.comBiotech Stocks Heat Up As Arvinas Scores Novartis Licensing Pact, Janux Reportedly Explores OptionsApril 10, 2024 | fool.comWhy Janux Therapeutics Stock Soared as the Market Sagged TodayApril 10, 2024 | msn.comJanux Therapeutics surges amid report of takeover interestApril 5, 2024 | morningstar.comJanux Therapeutics Inc Ordinary Shares JANXApril 5, 2024 | nasdaq.comCommit To Purchase Janux Therapeutics At $25, Earn 26.5% Annualized Using OptionsMarch 20, 2024 | msn.comCantor starts Janux at overweight, cites TCE leadership positionMarch 20, 2024 | markets.businessinsider.comForecasting The Future: 4 Analyst Projections For Janux TherapeuticsMarch 20, 2024 | finance.yahoo.comCancer-Focused Janux Therapeutics Platform Has 'Tremendous Opportunity': AnalystMarch 20, 2024 | benzinga.comCancer-Focused Janux Therapeutics Platform Has 'Tremendous Opportunity': Analyst - Janux Therapeutics (NASDAQ:JANX)March 15, 2024 | investorplace.comJANX Stock Earnings: Janux Therapeutics Beats EPS, Beats Revenue for Q4 2023March 15, 2024 | fool.com2 Stocks That Have More Than Tripled This Year: Are They Buys?March 14, 2024 | markets.businessinsider.comStranahan Recommends Buy on Janux Therapeutics with Increased Price Objective Amid Promising Drug AdvancesMarch 13, 2024 | markets.businessinsider.comB of A Securities Maintains Buy Rating for Janux Therapeutics: Here's What You Need To KnowMarch 8, 2024 | msn.comJanux Therapeutics GAAP EPS of -$0.25 beats by $0.16, revenue of $2.46M beats by $1.72MSee More Headlines Receive JANX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Janux Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/08/2024Today4/26/2024Next Earnings (Estimated)5/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:JANX CUSIPN/A CIK1817713 Webwww.januxrx.com Phone858-751-4493FaxN/AEmployees64Year FoundedN/APrice Target and Rating Average Stock Price Target$61.33 High Stock Price Target$100.00 Low Stock Price Target$35.00 Potential Upside/Downside+30.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($1.34) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-58,290,000.00 Net Margins-721.18% Pretax Margin-721.18% Return on Equity-17.88% Return on Assets-15.95% Debt Debt-to-Equity RatioN/A Current Ratio26.80 Quick Ratio26.80 Sales & Book Value Annual Sales$8.08 million Price / Sales301.14 Cash FlowN/A Price / Cash FlowN/A Book Value$7.46 per share Price / Book6.31Miscellaneous Outstanding Shares51,660,000Free Float33,372,000Market Cap$2.43 billion OptionableOptionable Beta4.18 Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesDr. David Alan Campbell Ph.D. (Age 64)President, CEO & Director Comp: $852.5kMr. Byron Robinson J.D. (Age 59)Ph.D., Chief Strategy Officer Comp: $606.8kMr. Tighe M. Reardon C.F.A. (Age 47)CPA, Acting Chief Financial Officer Mr. Charles M. Winter (Age 55)Chief Technical Officer Dr. Tommy Diraimondo Ph.D.Chief Scientific OfficerMr. James PenningtonGeneral CounselMs. Brenda Van VreeswykHead of Human ResourcesMr. Andy Hollman Meyer (Age 40)Chief Business Officer More ExecutivesKey CompetitorsIndiviorNASDAQ:INDVSummit TherapeuticsNASDAQ:SMMTEvotecNASDAQ:EVOMorphoSysNASDAQ:MORRhythm PharmaceuticalsNASDAQ:RYTMView All CompetitorsInsiders & InstitutionsAllspring Global Investments Holdings LLCSold 19,915 shares on 4/18/2024Ownership: 0.012%Janney Montgomery Scott LLCBought 51,548 shares on 2/8/2024Ownership: 0.112%Swiss National BankBought 9,000 shares on 2/6/2024Ownership: 0.069%Ventures Xi L.P. AvalonBought 849,854 shares on 11/13/2023Total: $4.99 M ($5.87/share)Ra Capital Management, L.P.Bought 495,008 shares on 7/19/2023Total: $6.17 M ($12.46/share)View All Insider TransactionsView All Institutional Transactions JANX Stock Analysis - Frequently Asked Questions Should I buy or sell Janux Therapeutics stock right now? 7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Janux Therapeutics in the last year. There are currently 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" JANX shares. View JANX analyst ratings or view top-rated stocks. What is Janux Therapeutics' stock price target for 2024? 7 Wall Street research analysts have issued 12-month target prices for Janux Therapeutics' shares. Their JANX share price targets range from $35.00 to $100.00. On average, they expect the company's share price to reach $61.33 in the next twelve months. This suggests a possible upside of 30.2% from the stock's current price. View analysts price targets for JANX or view top-rated stocks among Wall Street analysts. How have JANX shares performed in 2024? Janux Therapeutics' stock was trading at $10.73 on January 1st, 2024. Since then, JANX stock has increased by 339.0% and is now trading at $47.10. View the best growth stocks for 2024 here. Are investors shorting Janux Therapeutics? Janux Therapeutics saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 3,750,000 shares, an increase of 20.6% from the March 15th total of 3,110,000 shares. Based on an average daily trading volume, of 711,600 shares, the short-interest ratio is currently 5.3 days. Approximately 11.6% of the shares of the company are short sold. View Janux Therapeutics' Short Interest. When is Janux Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. View our JANX earnings forecast. How were Janux Therapeutics' earnings last quarter? Janux Therapeutics, Inc. (NASDAQ:JANX) issued its quarterly earnings results on Friday, March, 8th. The company reported ($0.25) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.37) by $0.12. The business earned $2.46 million during the quarter, compared to analysts' expectations of $0.98 million. Janux Therapeutics had a negative trailing twelve-month return on equity of 17.88% and a negative net margin of 721.18%. What ETFs hold Janux Therapeutics' stock? ETFs with the largest weight of Janux Therapeutics (NASDAQ:JANX) stock in their portfolio include Range Cancer Therapeutics ETF (CNCR), Loncar China Biopharma ETF (CHNA) and Fidelity Disruptive Medicine ETF (FMED).Principal Healthcare Innovators ETF (BTEC). When did Janux Therapeutics IPO? Janux Therapeutics (JANX) raised $152 million in an IPO on Friday, June 11th 2021. The company issued 9,500,000 shares at a price of $15.00-$17.00 per share. BofA Securities, Cowen and Evercore ISI served as the underwriters for the IPO and H.C. Wainwright & Co. LLC was co-manager. Who are Janux Therapeutics' major shareholders? Janux Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Allspring Global Investments Holdings LLC (0.01%). Insiders that own company stock include Corp Bregua, Orbimed Advisors Llc, Ra Capital Management, LP and Ventures Xi LP Avalon. View institutional ownership trends. How do I buy shares of Janux Therapeutics? Shares of JANX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:JANX) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithDid You Get Your Free Bitcoin Yet?Crypto Swap Profitstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyFed launches fourth dollar overhaulStansberry ResearchThe only accurate crypto trading system I know …Weiss RatingsBitcoin Rockets To Record High But Buy THIS InsteadParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Janux Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
